Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: Three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials

Clinical Drug Investigation

Volumn 30, Issue 9, 2010, Pages 613-624

  Schiff, Michael ^a   Beaulieu, Andre ^b   Scott, David L ^c   Rashford, Michelle ^d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Ciclosporin; Mycophenolate mofetil; Rheumatoid arthritis; therapeutic use; treatment

Indexed keywords

CREATININE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; EARLY TERMINATION OF CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYCOPHENOLIC ACID; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954653766     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11537460-000000000-00000     Document Type: Article

References (20)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001 Sep 15; 358 (9285): 903-911
2. Grassi W, De Angelis R, Lamanna G, et al. The clinical features of rheumatoid arthritis. Eur J Radiol 1998 May; 27 Suppl. 1: S18-24
3. Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clin Exp Immunol 2005 May; 140 (2): 195-204
4. Carter RH. B cells in health and disease. Mayo Clin Proc 2006 Mar; 81 (3): 377-384
5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46 (2): 328-346
6. Emery P. Treatment of rheumatoid arthritis. BMJ 2006 Jan 21; 332 (7534): 152-155
7. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005 Oct 15; 80 Suppl. 2: S181-90
8. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996 Feb; 10 (1 pt 2): 77-84
9. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993 Jun; 36 (6): 729-740
10. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. ArthritisRheum 1995 Jun; 38 (6): 727-735
11. Fries JF, Spitz P, Kraines RG, et al. Measurements of patient outcome in arthritis.Arthritis Rheum1980 Feb; 23 (2): 137-145
12. World Medical Association. World Medical Association Declaration ofHelsinki: recommendations guiding medical doctors in biomedical research involving human subjects (as amended in Hong Kong 1989) [online]. Available from URL: http://www.fda.gov/oc/health/helsinki89 [Accessed 2007 Sep 26]
13. Schiff M, Stein G, Leishman B. CellCept (mycophenolate mofetil-MMF), a new treatment for RA: a 9-month, randomized, double-blind trial comparing 1g bid and 2g bid. 61st Annual Meeting, American College of Rheumatology; 1997 Nov 8-12; Washington, DC
14. Hauck WW, Anderson S. A comparison of large-sample confidence interval methods for the difference in two binomial probabilities. Am Stat 1986; 40 (3): 18-322
15. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993 Mar-Apr; 11 Suppl. 8: S117-9
16. Johns KR, Littlejohn GO. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis. J Rheumatol 1999 Oct; 26 (10): 2110-2113
17. Altman RD, Schiff M, Kopp EJ. Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study. J Rheumatol 1999 Oct; 26 (10): 2102-2109
18. Machold KP, Nell VP, Stamm TA, et al. Aspects of early arthritis -traditional DMARD therapy: is it sufficient? Arthritis Res Ther 2006 May 15; 8 (3): 211
19. de Vries-Bouwstra JK, Dijkmans BA, Breedveld FC. Biologics in early rheumatoid arthritis. Rheum Dis Clin North Am 2005 Nov; 31 (4): 745-762
20. Ruderman EM. Current and future pharmaceutical therapy for rheumatoid arthritis. Curr Pharm Des 2005; 11 (5): 671-684